Seattle、WAにおける悪性黒色腫の臨床試験
Seattleとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- 他1件
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
被験者募集中第2相
- Fred Hutchinson Cancer Center ( Site 4041), Seattle
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
被験者募集中第3相
- Swedish Cancer Institute, Seattle
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
被験者募集中第3相
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17マイル先
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
被験者募集中第1/2相
- University of Washington Fred Hutchinson Cancer Center, Seattle
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
被験者募集中第2相
- Local Institution - 0086, Seattle
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
被験者募集中第2相
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Seattle Children's Hospital, Seattle
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
被験者募集中
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
被験者募集中第1相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Virginia Mason Medical Center, Seattle
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Fred Hutchinson Cancer Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
被験者募集中第3相
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Seattle
A Study of IBI363 in Subjects with Advanced Solid Malignancies
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Nashville, TN33件の研究
- Pittsburgh, PA31件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- St. Louis, MO21件の研究
- Salt Lake City, UT21件の研究
Seattleにおける他の研究
- 非小細胞肺癌53件の研究
- がん（全種類）49件の研究
- 前立腺がん42件の研究
- 急性骨髄性白血病40件の研究
- 乳がん39件の研究
- 転移性癌39件の研究
- 大腸癌34件の研究
- 肺がん33件の研究
- 卵巣がん30件の研究
- 多発性骨髄腫22件の研究
- 骨髄異形成症候群21件の研究
- 急性リンパ性白血病21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。